Economics of first-line treatment with tislelizumab in patients with nonsquamous non-small cell lung cancer.

Objective: This study evaluates the cost-effectiveness of tislelizumab plus chemotherapy as a first-line treatment for locally advanced or metastatic (IIIB/IV) nonsquamous non-small cell lung cancer (nsq-NSCLC) in China.

Methods: A Markov model projected health outcomes and costs over a lifetime, with health states including progression-free survival, progressive disease, terminal progressive disease (TPD) and death. Data came from a Chinese phase III trial.

Effectiveness of cascading time series models based on meteorological factors in improving health risk prediction.

Meteorological factors, which are periodic and regular in a long run, have an unignorable impact on human health. Accurate health risk prediction based on meteorological factors is essential for optimal allocation of resource in healthcare units. However, due to the non-stationary and non-linear nature of the original hospitalization sequence, traditional methods are less robust in predicting it.